Collegium Pharmaceutical (Cumberland, RI) a clinical-stage small molecule company focused on the development of innovative treatments for chronic pain, closed a $22.5M Series B financing. Participants include Longitude Capital, Skyline Ventures, Frazier Healthcare Ventures and Boston Millennia Partners.